Moreover, analysis of Kaplan–Meier survival datasets showed that lower expression of ARAP1, even in tumor tissues of early-stage, was closely associated with poorer overall survival (OS) and progression-free survival (PFS) in LUAD patients (Fig. 1A, B and S1C, D). The gene discussed is ARAP1; the disease is neoplasm.